Genmab — Juni 2020

[E_L]

Sarclisa made $ 1mio revenue in Q1. Good luck against Dara SC.

[StockBull]

Derudover ligger DAX og SP500 også an til retracement ud fra TA men det er da muligt Trump kan ryste en jocker ud af ærmet

[StockBull]

[JohnW]

Er Sarclisa godkendt i US, eller kun i EU? Hvilke behandlingslinier er det godkendt til?

[Bulder]

Begge steder nu. EU forleden. US i marts. 3. linje med pom+dex

[Bulder]

Input string was not in a correct format.

(www.pharmabiz.com)

[JohnW]

Tak @Bulder. Hvor lang tid vil det mon tage dem at blive godkendt i 2. linie og 1. linie? Kan Darzalex mon nå at blive fuldt etableret standard of care i 1. linie før Sarclisa bliver godkendt i 1. linie?

[Bulder]

Isa+CyBorD i 1. linje er i fase 1, så der er nogen tid endnu. https://www.clinicaltrials.gov/ct2/show/NCT02513186?term=isatuximab+mm&draw=2&rank=2

[JohnW]

Tak for link.

[Bulder]

Studiet ovenfor er også Isa+RVd. Her er dara forlængst i fase 3 med Cepheus-studiet, og i forvejen godkendt med Rd i non-asct-setting.

[GeorgeBest]

Genmab to Participate in a Virtual Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference https://ir.genmab.com/news-releases/news-release-details/genmab-participate-virtual-fireside-chat-goldman-sachs-41st

[GeorgeBest]

kl. 21 i dag

[GeorgeBest]

korrektion kl 21 den 11. juni

[GeorgeBest]

hhmm Antony Pagano i stedet for JvdW

[E_L]

this SY-1425 combi for MDS seems fully recruited, didn't thinke we would hear from that again, primary completion date this month, maybe we can get some data at some point https://clinicaltrials.gov/ct2/history/NCT02807558?A=14&B=15&C=merged#StudyPageTop

[BioShare]

Jan har ikke tid...kan bare ikke den dag....han har nogle papirer som skal underskrives.....

[Vitus]

Hvordan skal det lige forståes ?

[gdn55]

Jo, eller barsel

[E_L]

@kkjoel so you were right; it was 15

[E_L]

https://www.globenewswire.com/news-release/2020/06/04/2043780/0/en/Genmab-Announces-European-Marketing-Authorization-for-the-Subcutaneous-Formulation-of-DARZALEX-daratumumab-for-the-Treatment-of-Patients-with-Multiple-Myeloma.html